Reema Zeineldin, Ph.D.

Advantages of targeting:

Reduces nonspecific cytotoxicity

Selectively direct nanocarriers to specific endocytic compartments or intracellular organelles

Design linkers to release drugs in the endosome to which the nanocarrier is directed

Application to therapy of cancers expressing certain receptors

Candidate receptors in ovarian cancer:

Epidermal growth factor receptor
Folate receptor alpha